Borghi A, et al. – The intent of this study was to examine i) the rate of vulvar lichen sclerosus (VLS) patients who achieved complete clearance of symptoms or objective features, or both, with a 12–week pharmacological treatment and ii) the predictive value of therapeutic response of the demographic and clinical features. It was determined that a relevant part of patients undergoing a 12–week topical therapy were not completely cured of VLS. The assumption put forth was that these patients, regardless of a marked improvement, could display a substantial residual disease, hence, its effect on their quality of life.